Longevity play TMRW raises $7m seed round from Tidal and inks TruDiagnostic deal — Capital Brief
Printed
by
for personal, non-commercial use only.
For other rights, contact
licensing@capitalbrief.com.
The longevity platform founded by former iflix CEO Mark Britt has closed its first VC round — backed, in large part, by its own members
Tmrw CEO Mark Britt.
Supplied.
Your cells have an age, and it is not the same as your birthday. Working that out has become a booming industry.
While blood diagnostics have become the bread and butter of a thousand new health platforms, most will hand you a PDF with 30 data points and call it done. TMRW CEO Mark Britt is building on 1,700.
TMRW has raised approximately $7 million in seed funding to expand its clinical footprint and refine the patient experience, moving beyond digital-only health tools to a proactive clinical environment.
The round was led by Sydney-based Tidal Ventures, with participation from Melbourne fund Capital Zed and a cohort of high-net-worth entrepreneurs and family offices — the majority of whom are active TMRW members themselves.
Topics:
Startups,
Venture capital,
Startup funding
Sign up to Sweat Equity
Sign up to Sweat Equity
Signed up to Sweat Equity
Sign up to The Edition
Sign up to The Edition
Signed up to The Edition
Sign up to Standup
Sign up to Standup
Signed up to Standup
© 2026 Capital Brief Pty Ltd
Close
Your email address will be stored in accordance with our
privacy policy.